Prognostic evaluation of primary non-small cell lung carcinoma patients using biological fluid variables. A systematic review

REFERENCES

• American Thoracic Society European Respiratory Society. Pre-treatment evaluation of non-small-cell lung cancer. Am J Respir Crit Care Med 1997; 156: 320–32.
   PubMedGoogle Scholar
• Bruderman I. Bronchogenic carcinoma. In: Baum GL, Wolinsky E, editors. Texbook of pulmonary diseases, 5th ed. New York: Little, Brown and Company; 1994. p. 1345–92
   Google Scholar
• Ginsberg RJ, Kris MG, Armstrong JG. Non-small cell lung cancer. In: De Vita VT, Hellman S, Rosenberg SA. Cancer. Principles and practice of oncology, 4th ed. Philadelphia: JB Lippincott Company; 1993. p. 673–723
   Google Scholar
• Ginsberg RJ. Continuing controversies in staging NSCLC: an analysis of the revised 1997 staging system. Oncology 1998; 12 Suppl 2: 51–4.
   PubMed Web of Science ®Google Scholar
• Naruke T, Tsuchiya R, Kondo H, Asamura H, Nakayama H. Implications of staging in lung cancer. Chest 1997; 112: 242S–8S.
   Google Scholar
• Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980; 65: 25–32.
   PubMed Web of Science ®Google Scholar
• Fielding LP, Fenoglio-Preiser CM, Freedman LS. The future of prognostic factors in outcome prediction for patients with cancer. Cancer 1992; 70: 2367–7.
   PubMed Web of Science ®Google Scholar
• Société de pneumologie de langue francaise. Recommandations concernant l'utilisation des marqueurs tumouraux sériques dans la prise en charge des cancers bronchiques primitifs. Rev Mal Resp 1997; 14: 3S5–39.
   Google Scholar
• Watine J, Charet JC. Do blood cell counts and/or differential have an independent pre-therapeutic prognostic value in primary lung cancer? Hematol Cell Ther 1998; 40: 99–106.
   PubMedGoogle Scholar
• Buccheri G, Ferrigno D. Prognostic factors in lung cancer: tables and comments. Eur Respir J 1994; 7: 1350— 64.
   PubMed Web of Science ®Google Scholar
• Watine J, Charet JC. Faut-il suivre les sociétés savantes de pneumologie dans leurs recommanda-tions concernant l'utilisation des marqueurs tumouraux sériques dans l'évaluation pronostique des cancers bronchiques primitifs non à petites cellules? Rev Mal Respir 1999; 16: 139-49. (correspondence de N. Roche et al. in: Rev Mal Respir 1999; 16: 1165–6)
   PubMed Web of Science ®Google Scholar
• Sandberg S, Oosterhuis W, Freedman D, Kawai T. Systematic reviewing in laboratory medicine. Position paper from the IFCC committee on systematic reviewing in laboratory medicine. J Int Fed Clin Chem 1997; 9: 154–5.
   PubMedGoogle Scholar
• Vamvakas EC. Meta-analyses of studies of the diagnostic accuracy of laboratory tests. A review of the concepts and methods. Arch Pathol Lab Med 1998; 122: 675–86.
   PubMed Web of Science ®Google Scholar
• Charet JC, Watine J, Lepretre A, Raimbault C, Charet P. Orosomucoid: prealbumin ratio in the monitoring of lung cancer. Clin Biochem 1996; 29: 287–90.
   Google Scholar
• Watine J, Rouzaud P, Charet JC. Analyse critique de la bibliographie sur l'utilisation des paramètres biologiques sanguins pour l'évaluation pronos-tique du cancer broncho-pulmonaire primitif. Ann Biol Clin 1999; 57: 57–68.
   Google Scholar
• Cox DR. Regression models and life-tables (with discussion). JR Stat Soc 1972; B34: 187–202.
   Google Scholar
• Ciampi A, Thiffault J. Recursive partitioning and amalgamation (RECPAM) for censored survival data: criteria for tree selection. Statistical Software Newsletter 1988; 14: 78–81.
   Google Scholar
• Watine J. Laboratory variables as additional staging parameters in patients with small-cell lung carcinoma. A systematic review. Clin Chem Lab Med 1999; 37: 931–8.
   PubMed Web of Science ®Google Scholar
• Albain KS, Crowley JJ, Leblanc M, Livingston RB. Survival determinants in extensive stage non-small cell lung cancer: the Southwest Oncology Group Experience. J Clin Oncol 1991; 9: 1618–26.
   PubMed Web of Science ®Google Scholar
• Andoh M, Gemma A, Takenaka K, Hisakatsu S, Yamada K, Usuki J, Hasegawa K, Sakoni M, Kudoh S, Tsuboi E, Nitani H. Serum neuron specific enolase level as a prognostic factor in non-small cell lung cancer. Intern Med 1994; 33: 271 — 6.
   Google Scholar
• Benichou J, Fabre Ch, Chastang Cl, Lebeau B, Babo P, Rebishung JL, Lepage T, Fichet D, Decroix G. Facteurs pronostiques du cancer du poumon opéré non à petites cellules: étude a partir d'un essai thérapeutique randomisé. Rev Mal Respir 1987; 4: 301–9.
   Google Scholar
• Bréchot JM, Chevret S, Nataf J, Le Gall C, Frétault J, Rochemaure J, Chastang Cl. Diagnos-tic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non- small-cell lung cancer: a prospective study of 116 patients. Eur J Cancer 1997; 33: 385–91.
   Google Scholar
• Buccheri G, Ferrigno D, Vola F. Carcinoembryo-nic antigen (CEA), tissue polypeptide antigen (TPA) and other prognostic indicators in squa-mous cell lung cancer. Lung Cancer 1993; 10: 21 — 33.
   Google Scholar
• Carles J, Rose11 R, Ariza A, Pellicer I, Sanchez JJ, Femandez-Vasalo G, Abad A, Bamadas A. Neuroendocrine differentiation as a prognostic factor in non-small-cell lung cancer. Lung Cancer 1993; 10: 209–19.
   PubMed Web of Science ®Google Scholar
• Diez M, Torres A, Pollan M, Gomez A, Ortega D, Maestro ML, Granell J, Balibrea JL. Prognostic significance of serum CA125 antigen assay in patients with non-small-cell lung cancer. Cancer 1994; 73: 1368–76.
   PubMed Web of Science ®Google Scholar
• Engan T, Hannisdal E. Blood analyses as prog-nostic factors in primary lung cancer. Acta Oncol 1990; 29: 151–4.
   PubMed Web of Science ®Google Scholar
• Espinoza E, Feliu J, Zamora P, Gonzalez-Baron M, Sanchez JJ, Ordonez A, Espinoza J. Serum albumin and other prognostic factors related to response and survival in patients with advanced non-small-cell lung cancer. Lung Cancer 1995; 12: 67–76.
   Google Scholar
• Evans WK, Nixon DW, Daly JM, Ellenberg SS, Gardner L, Wolfe E, Shepherd FA, Feld R, Gralla R, Fine S, Kemeny N, Jeejeebhoy KN, Heymsfield S, Hoffman FA. A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer. J Clin Oncol 1987; 5: 113 — 4.
   Web of Science ®Google Scholar
• Ferrigno D, Buccheri G, Camilla T. Serum copper and zinc content in non-small-cell lung cancer: abnormalities and clinical correlates. Monaldi Arch Chest Dis 1999; 54: 204–8.
   Google Scholar
• Foa P, Fomier M, Miceli R, Seregni E, Santambrogio L, Nosotti M, Cataldo I, Sala M, Caldiera S, Bombardieri E. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small-cell lung cancer. Anticancer Res 1999; 19: 3613–8.
   Google Scholar
• Fukuoka M, Masuda N, Furuse K, Negoro S, Takada M, Matsui K, Takifuji N, Kudoh S, Kawahara M, Ogawara M, Kodama N, Kubota K, Yamamoto M, Kusunoki Y. A randomized trial in inoperable non-small-cell lung cancer; vindesine and cisplatin versus mitomycin, vinde-sine and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin. J Clin Oncol 1991; 9: 606–13.
   PubMed Web of Science ®Google Scholar
• Hespanhol V, Queiroga H, Magalhaes A, Santos AR, Coelho M, Marques A. Survival predictors in advanced non-small-cell lung cancer. Lung Cancer 1995; 13: 253–67.
   PubMed Web of Science ®Google Scholar
• Hirashima T, Takada M, Komiya T, Nitta T, Masashi K, Masuda N, Matui K, Kikui M, Yasumitsu T, Kawase I. Prognostic significance of CYFRA 21-1 in non-small-cell lung cancer. Anticancer Res 1998; 18: 4713–6.
   PubMed Web of Science ®Google Scholar
• Kawahara M, Furuse K, Kodama N, Yamamoto M, Kubota K, Takada M, Negoro S, Kusunoki Y, Matui K, Takifuji N, Fukuoka M. A randomized study of cisplatin versus cisplatin plus vindesin for non-small-cell lung carcinoma. Cancer 1991; 68: 714 — 9.
   Google Scholar
• Komiya T, Hirashima T, Takada M, Masuda N, Yasumitsu T, Nakagawa K, Hosono Y, Kikui M, Tsuji S, Fukuoka M, Kawase I. Prognostic significance of p53 antibodies in squamous cell carcinoma of the lung. Anticancer Res 1997; 17: 3721 — 4.
   Google Scholar
• Laudanski J, Burzykowski T, Niklinska W, Chyczewski L, Furman M, Niklinski L. Prognostic value of serum p53 antibodies in patients with resected non-small-cell lung cancer. Lung Cancer 1998; 22: 191–200.
   PubMed Web of Science ®Google Scholar
• Masutani M, Akusawa H, Kadota A, Ohchi Y, Takahashi N, Tanigawa S, Koya Y, Hone T. A phase III randomized trial of cisplatin plus vindesine versus cisplatin plus vindesine plus mitomycin C versus cisplatin plus vindesine plus ifosfamide for advanced non-small-cell lung cancer. Respirology 1996; 1: 49–54.
   PubMedGoogle Scholar
• Moro D, Villemain D, Vuillez JP, Agnius Delord C, Brambilla C. CEA, CYFRA 21–1 and SCC in non-small-cell lung cancer. Lung Cancer 1995; 13: 169— 76.
   Google Scholar
• Muers MF, Shevlin P, Brown J, on behalf of the participating members of the Thoracic Group of the Yorkshire Cancer Organisation. Prognosis in lung cancer: physicians' opinions compared with outcome and a predictive model. Thorax 1996; 51: 894— 902.
   Google Scholar
• Niklinski J, Furman M, Burzykowski T, Chyczewski L, Chyczewska E, Rapellino M. Preoperative CYFRA 21-1 level as a prognostic indicator in resected primary squamous cell lung cancer. Br J Cancer 1996; 74: 956–60.
   PubMed Web of Science ®Google Scholar
• Niklinski J, Burzykowski T, Niklinska W, Laudanski J, Chyczewski L, Chyczewska E, Rapellino M, Furman M. Preoperative CYFRA 21-1 level as a prognostic indicator in resected nonsmall cell lung cancer. Eur Respir J 1998; 12: 1424 — 8.
   PubMed Web of Science ®Google Scholar
• Nisman B, Lafair J, Heching N, Lyass 0, Baras M, Peretz T, Barak V. Evaluation of tissue polypeptide specific antigen, cyfra 21-1, and carcinoembryonic antigen in non-small-cell lung carcinoma: does the combined use of cytokeratin markers give any additional information? Cancer 1998; 82: 1850–9.
   Google Scholar
• Nisman B, Amir G, Lafair J, Heching N, Lyass 0, Peretz T, Barak V. Prognostic value of Cyfra 21–1, TPS and CEA in different histologic types of non-small cell lung cancer. Anticancer Res 1999; 19: 3549— 52.
   Google Scholar
• O'Connell JP, Kris MG, Gralla RJ, Groshen S, Trust A, Fiore JJ, Kelsen DP, Heelan RT, Golbey RB. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol 1986; 4: 1604–14.
   PubMed Web of Science ®Google Scholar
• Ohlhauser C, Biilzebruck H, Ebert W, Drings P, Wannenmacher M. Prognostic factors for survival in inoperable non-small-cell lung cancer: a multi-variate regression analysis of 456 patients with radiation therapy. Onkologie 1997; 20: 126–31.
   Google Scholar
• Pujol JL, Cooper EH, Grenier J, Purves DA, Lehmann M, Ray P, Aouta MD, Bashir M, Godard P, Michel FB. Clinical evaluation of serum tissue polypeptide antigen (TPS) in non-small-cell lung cancer. Eur J Cancer 1994; 30A: 1768–74.
   PubMed Web of Science ®Google Scholar
• Pujol JL, Grenier J, Parrat E, Lehmann M, Lafontaine M, Quantin X, Michel FB. Cyto-keratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS. Am J Respir Crit Care Med 1996; 154: 725–33.
   Google Scholar
• Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Ewans WK, Hodson DI, Clark DA, Feld R, Arnold AM, Ayoub JI, Wilson KS, Latreille J, Wierzbicki RF, Hill DP. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer: report of a Canadian multicenter randomized trial. J Clin Oncol 1988; 6: 633–41.
   Google Scholar
• Ray P, Quantin X, Grenier J, Pujol JL. Predictive factors of tumour response and prognostic factors of survival during lung cancer chemotherapy. Cancer Detect Prey 1998; 22: 293–304.
   PubMedGoogle Scholar
• Rechnitzer S, Biilzebruck H, Ebert W, Drings P. Pretreatment prognostic factors for survival in non-small-cell lung cancer: a multivariate analysis of 229 patients. Onkologie 1998; 21: 204–10.
   Google Scholar
• Sculier JP, Paesmans M, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, Van Cutsem 0, Schmerber J, Giner V, Berchier MC, Sergysels R, Mommen P, Klastersky et les membres de l'European Lung Cancer Working Party. Facteurs pronostiques des cancers bronchiques non à petites cellules au stade avancé. Experience de l'European Lung Cancer Working Party. Rev Mal Respir 1997; 14: 445–9.
   Google Scholar
• Shinkai T, Eguchi K, Sasaki Y, Tamura T, Ohe Y, Kojima A, Oshita F, Miya T, Okamoto H, Iemura K, Saijo N. A prognostic-factor risk index in advanced non-small-cell lung cancer treated with cisplatin-containing combination chemotherapy. Cancer Chemother Pharmacol 1992; 30: 1–6.
   Google Scholar
• Sorensen JB, Badsberg JH, Olsen J. Prognostic factors in inoperable adenocarcinoma of the lung: a multivariate regression analysis of 259 patients. Cancer Res 1989; 49: 5748–54.
   Google Scholar
• Sorensen JB, Badsberg JH. Prognostic factors in resected stage I and II adenocarcinomas of the lung. A multivariate regression analysis of 137 consecutive patients. J Thorac Cardiovasc Surg 1990; 99: 218–26.
   PubMed Web of Science ®Google Scholar
• Sugiura S, Ando Y, Minami H, Ando M, Sakai S, Shimokata K. Prognostic value of pleural effusion in patients with non-small-cell lung cancer. Clin Cancer Res 1997; 3: 47–50.
   PubMed Web of Science ®Google Scholar
• Takigawa N, Segawa Y, Okahara M, Maeda Y, Takata I, Kataoka M, Fujii M. Prognostic factors for patients with advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgama-tion. Lung Cancer 1996; 15: 67–77.
   Google Scholar
• Van der Gaast A, Schoenmakers CHH, Kok TC, Blijenberg BG, Hop WCJ, Splinter TAW. Prog-nostic significance of tissue polypeptide-specific antigen (TPS) in patients with advanced non-small-cell lung cancer. Eur J Cancer 1994; 30A: 1783— 6.
   PubMed Web of Science ®Google Scholar
• Van Zandwijk N, Jassem E, Bonfrer JMG, Mooi WJ, Van Tinteren H. Serum neuron-specific enolase and lactate dehydrogenase as predictors of response to chemotherapy and survival in non-small-cell lung cancer. Semin Oncol 1992; 19 Suppl 2: 37–43.
   Google Scholar
• Wieskopf B, Demangeat C, Purohit A, Stenger R, Gries P, Kreisman H, Quoix E. Cyfra 21-1 as a biologic marker of non-small-cell lung cancer. Chest 1995; 108: 163–9.
   Google Scholar
• Wojtukiewicz MZ, Zacharski LR, Moritz TE, Hur K, Edwards RL, Rickles FR. Prognostic signifi-cance of blood coagulation tests in carcinoma of lung and colon. Blood Coag Fibrin 1992; 3: 429–37.
   PubMed Web of Science ®Google Scholar
• Cristofori R, Aimo G, Mengozzi G, Oliaro A, Revello F, Rapellino M. Tumour markers kinetic in malignant lung neoplasms. J Cardiovasc Surg 1999; 40: 299–305.
   PubMed Web of Science ®Google Scholar
• Sanders GT, Kelly AM, Breuer J, Kohse KP, Mocarelli P, Sachs C. Guide to the EC4 register European Clinical Chemist. Eur J Clin Chem Clin Biochem 1997; 35: 797–803.
   PubMedGoogle Scholar
• Touitou Y, Haus E, editors. Biologic rhythms in clinical and laboratory medicine. Heidelberg: Springer-Verlag; 1994
   Google Scholar
• Watine J, Miedouge M. Pre-analytical variation of laboratory variables. Clin Chem Lab Med 2000. In press
   Google Scholar
• Johnson BE. Biologic and molecular prognostic factors—impact of treatment of patients with non-small-cell lung cancer. Chest 1995; 107 Suppl 6: 287S–90S.
   Google Scholar
• Spiridonidis CH, Laufman LR, Stydnicki KA, Noltimier JW, Cho CC, Young DC, Hicks WJ, Segal ML, Guy JT. Decline of posttreatment tumour marker levels after therapy of nonsmall cell lung cancer. A useful outcome predictor. Cancer 1995; 75: 1586–93.
   Google Scholar
• Van der Gaast A, Schoenmakers CHH, Kok TC, Blijenberg BG, Comillie F, Splinter TAW. Eva-luation of a new tumour marker in patients with non-small-cell lung cancer: CYFRA 21-1. Br J Cancer 1994; 69: 525–8.
   PubMed Web of Science ®Google Scholar
• Watine J. Further comments. A clinical biologist's point of view. Concerning Rechnitzer S, et al.: "Pretreatment prognostic factors for survival in non-small-cell lung cancer: a multivariate analysis of 229 patients". Onkologie 1998; 21: 510–11.
   Google Scholar
• Ohlsson A. Systematic reviews—theory and prac-tice. Scand J Clin Lab Invest Suppl 1994; 219: 25–32.
   PubMedGoogle Scholar
• Watine J. Prognostic score for Hodgkin's disease. N Engl J Med 1999; 340: 1289.
   PubMed Web of Science ®Google Scholar
• Von Eyben FE, Petersen PH, Blaabjerg 0, Madsen EL. Analytical quality specifications for serum lactate dehydrogenase isoenzyme 1 based on clinical goals. Clin Chem Lab Med 1999; 37: 553— 61.
   Google Scholar
• Finkelstein DM, Ettinger DS, Ruckdeschel JC. Long-term survivors in metastatic non-small-cell lung cancer: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1986; 4: 702–9.
   Google Scholar
• Gail MH, Eagan RT, Feld R, Ginsberg R, Goodell B, Hill L, Holmes EC, Lukeman JM, Mountain CF, Oldham RK, Pearson G, Wright PW, Lake WH and the lung cancer study group. Prognostic factors in patients with resected stage I non-small-cell lung cancer. A report from the lung cancer study group. Cancer 1984; 54: 1802–13.
   Google Scholar
• Hamzaoui A, Thomas P, Castelnau 0, Roux N, Roux F, Kleisbauer JP. Usefulness of longitudinal evaluation of Cyfra 21-1 variations in advanced lung cancer monitoring. Lung Cancer 1997; 16: 191–202.
   PubMed Web of Science ®Google Scholar
• Yoshimasu T, Miyoshi S, Maebeya S, Suzuma T, Bessho T, Hirai I, Tanino H, Arimoto J, Naito Y. Analysis of the early postoperative serum carci-noembryonic antigen time-course as a prognostic tool for bronchogenic carcinoma. Cancer 1997; 79: 1533–40.
   Google Scholar
• Durand-Zalesky I, Rymer JC, Roudot-Thoraval F, Revuz J, Rosa J. Reducing unnecessary laboratory use with new test request form: example of tumour markers. Lancet 1993; 342: 150 — 3.
   Google Scholar
• Vassilopoulou-Sellin R, Newman BM, Taylor SH, Guinee VF. Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center. Cancer 1993; 71: 1309–12. (com-ments in volume 72: 956-7)
   Google Scholar
• Bushinsky DA, Monk RD. Calcium. Lancet 1998; 352: 306 — 11.
   PubMed Web of Science ®Google Scholar
• Giraudet P, Coudon B, Postel P, Alexandre JA. Profils protéiques. Behring Diagnostic, Rueil-Malmaison. Editions Publigrafic, Poissy, France; 1992
   Google Scholar
• Plaisier E, Mougenot B, Moulin B, Ronco P. Glomérulopathies paranéoplasiques. Méd Thér 1997; 3: 717–25.
   Google Scholar
• Pedersen LM, Milman N. Prevalence and prog-nostic significance of proteinuria in patients with lung cancer. Acta Oncol 1996; 6: 691–5.
   Web of Science ®Google Scholar
• Pedersen LM, Milman N. Microalbuminuria in patients with lung cancer. Eur J Cancer 1998; 34: 76 — 80.
   PubMed Web of Science ®Google Scholar
• Vinolas N, Molina R, Galan MC, Casas F, Callejas MA, Filella X, Grau JJ, Ballesta AM, Estape J. Tumour markers in response monitoring and prognosis of non-small cell lung cancer: preliminary report. Anticancer Res 1998; 18: 631— 4.
   Google Scholar
• Bergqvist M, Brattstrom D, Hesselius P, Wiklund B, Silen A, Wagenius G, Brodin 0. Cytokeratin 8 and 18 fragments measured in serum and their relation to survival in patients with non-small-cell lung cancer. Anticancer Res 1999; 19: 1833–6.
   Google Scholar
• Gomm SA, Keevil BG, Thatcher N, Hasleton PS, Swindell RS. The value of tumour markers in lung cancer. Br J Cancer 1988; 58: 797–804.
   PubMed Web of Science ®Google Scholar
• Watine J. Further comments on: "Prognostic impact of an activation of coagulation in lung cancer". Ann Oncol 1998; 9: 1255–6.
   PubMed Web of Science ®Google Scholar